# BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer

> **NCT00004122** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute**

## Conditions studied

- Bladder Cancer

## Interventions

- **BIOLOGICAL:** BCG vaccine
- **BIOLOGICAL:** recombinant interferon alfa

## Key facts

- **NCT ID:** NCT00004122
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-07
- **Primary completion:** 2001-04
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004122, "BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00004122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*